Tina Buehner, PhD (@tina_buehner) 's Twitter Profile
Tina Buehner, PhD

@tina_buehner

Past President SNMMI-TS. Scientist, Oncology Research-Women’s Health. Proud Mom. WFPB. Views are my own.

ID: 993103852453982208

linkhttps://orcid.org/0000-0002-4001-6547 calendar_today06-05-2018 12:23:04

145 Tweet

149 Followers

145 Following

Andrei Gafita (@dragafita) 's Twitter Profile Photo

Superb work using AI for automatic treatment response evaluation in prostate cancer. #RECIP validated in early stage prostate cancer in patients with BCR and low tumor burden. link.springer.com/article/10.100…

Superb work using AI for automatic treatment response evaluation in prostate cancer.

#RECIP validated in early stage prostate cancer in patients with BCR and low tumor burden.

link.springer.com/article/10.100…
SNMMI (@snm_mi) 's Twitter Profile Photo

A new imaging agent, ⁶⁸Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic #BreastCancer patients, according to new research published in JNM. ow.ly/8ijo50PQaEf #NuclearMedicine #MedicalImaging JNM

A new imaging agent, ⁶⁸Ga-ABY-025, can predict early metabolic response to HER2-targeted treatment in HER2-positive metastatic #BreastCancer patients, according to new research published in JNM. ow.ly/8ijo50PQaEf 

#NuclearMedicine #MedicalImaging <a href="/JournalofNucMed/">JNM</a>
SNMMI (@snm_mi) 's Twitter Profile Photo

Breaking News: The FDA has approved the imaging agent Technegas for use in ventilation–perfusion (V/Q) studies to diagnose respiratory disease. ow.ly/zeo050PQMI3 #NuclearMedicine #LungDisease

Breaking News: The FDA has approved the imaging agent Technegas for use in ventilation–perfusion (V/Q) studies to diagnose respiratory disease. ow.ly/zeo050PQMI3
#NuclearMedicine #LungDisease
Tina Buehner, PhD (@tina_buehner) 's Twitter Profile Photo

Roller coasters and rides until 1am with some of my favorite Nuclear Nerds ☢️ Epcot Centre SNMMI Midwinter meeting #epcot #epcotafterdark #nuclearmedicine #snmmi #mwm2024

Roller coasters and rides until 1am with some of my favorite Nuclear Nerds ☢️ <a href="/EpcotCentre/">Epcot Centre</a> SNMMI Midwinter meeting #epcot #epcotafterdark #nuclearmedicine 
#snmmi #mwm2024
SNMMI (@snm_mi) 's Twitter Profile Photo

8 million people every year use #nuclearmedicine to screen for and diagnose #heartdisease to avoid more expensive or invasive procedures. Dr. Dilsizian, Chief of Nuclear Medicine at the Univ. of Maryland, tells us more on FOX 5 DC:

Michael Hofman (@drmhofman) 's Twitter Profile Photo

Important study: more than 6 cycles of Lu-177 PSMA is both and safe and efficacious. For patients who benefited from initial cycles, there is an urgent need to enable global access to more cycles of effective treatment.

Tina Buehner, PhD (@tina_buehner) 's Twitter Profile Photo

"Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?" has been accepted for presentation at the EANM meeting! Thrilled to present this data in Germany on behalf of our incredible team. #EANM2024 #PSMA #UAZMedImaging #ProstateCancer #PrecisionMedicine Bital Savir-Baruch MD, FACNM

Michael Hofman (@drmhofman) 's Twitter Profile Photo

Clinical Trial Protocol for VIOLET Terbium-161 PSMA Phase I/II now online JNM Tb-161: Auger and conversion electrons that deposit a higher concentration of radiation over a shorter path, particularly to single tumor cells and micrometastases.

Clinical Trial Protocol for VIOLET Terbium-161 PSMA Phase I/II now online <a href="/JournalofNucMed/">JNM</a> 

Tb-161: Auger and conversion electrons that deposit a higher concentration of radiation over a shorter path, particularly to single tumor cells and micrometastases.